Bias risk assessment of included studies. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for hs-CRP. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for IL-6. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The incidence rate of adverse reactions. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The PRISMA study flowchart. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for FEV1/FVC. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for FEV1. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

The excluded and included studies were listed. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for PaCO₂. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for PaO₂. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Relative expression of hub genes. by Ziyang Liu (242055)

XRD diffraction pattern spectra of PFAgNPs. by Kenedy Kiyimba (9942393)

“…The no observed adverse effect level was 50 mg/kgBW, the lowest observed adverse effect level was 100 mg/kgBW, and median lethal dose (LD₅₀) was 1000 mg/kg. The PFAgNPs significantly decreased (<i>P</i> < 0.05) serum proteins, cholesterol, estrogen and progesterone alongside preservation of the histoarchitecture of the uterus. …”

pone.0331193.t003 - by Carol Kotliar (22351525)

“…</p><p>Design</p><p>Pilot clinical study, active-controlled, open randomization.…”

Baseline characteristics by group. by Carol Kotliar (22351525)

“…</p><p>Design</p><p>Pilot clinical study, active-controlled, open randomization.…”

<i>Rab23</i> deletion perturbs ciliation in a context-dependent manner. by Wan Ying Leong (22075947)

Quantifying bactericidal effects of cold Ar-CAPP against diverse <i>E. coli</i> strains. by Elanie F. Briggs (22103678)

Plants components in five-flower remedy [24]. by Walaiporn Plirat (17775628)

“…Histological analysis revealed decreased brain hemorrhage, leukocyte infiltration, and neuronal apoptosis. …”

Photomicrograph of the gastric mucosa colored with an anti-caspase-3 antibody. by Rehab F. Taher (20478600)

Macroscopic results of the protective impacts of <i>P. maritimum</i> extract (PM-EtOH) on ethanol induced-stomach mucosal damage in rats. by Rehab F. Taher (20478600)

Secondary and tertiary outcomes. by Maram Khaled (14642937)

“…Primary outcome is pain intensity with movement (elicited by asking the patient to move from supine to sitting position) using 0–10 Numerical Rating Scale (0 = no pain, 10 = worst possible pain).</p><p>Significance</p><p>The results of this study may result in improved pain control, maternal satisfaction and wound healing; decrease the use of perioperative opioids; potentially decrease the incidence of postpartum depression and persistent pain; and overall lead to better postoperative outcomes thereby decreasing healthcare costs.…”